The Center for Medicinal Cannabis Research (CMCR) is seeking to fund cannabis-related studies that further enhance the understanding of the efficacy and adverse effects of cannabis and cannabinoids as pharmacological agents for the treatment of medical and psychiatric disorders, and their potential public health impacts. Two award types are available. Primary project awards will be up to $275,000 in total costs (direct and indirect) per year for up to three years. Pilot project awards will be up to $150,000 in total costs (direct and indirect) per year for up to two years.
Letter of Intent Due
March 15, 2022 2 pm PDT
June 2, 2022 2 pm PDT
July - August 2022
Earliest Start Date
October 1, 2022
Funding priorities include studies that 1) provide proof-of-principle findings that inform future, more comprehensive studies, 2) address scientific gaps identified by the emerging literature 3) represent promising new directions for research.
Although the CMCR focus is on the therapeutic potential of cannabis , applications may address adverse effects of cannabis (e.g., effects on cognition; mental health; driving and public safety; drug-drug interactions), and effects on certain populations (eg, elderly, women’s health). Applications addressing the role of cannabinoids in COVID will also be considered.
The CMCR will also consider basic science and animal studies with clear translational implications for human health and disease. Studies of assays/methods for detection of cannabinoids, endocannabinoids, related substances are likewise eligible. However, CMCR is not in a position to support new drug development.
Proof of principle clinical studies are encouraged, as are proposals that leverage other funding (e.g., from other grant sources, foundations, in-kind contributions of equipment or services, etc.). Applicants are encouraged to consider psychoactive cannabinoids (e.g., delta-9-tetrahydrocannabinol, THC; delta 8 THC) as well as well as “minor” cannabinoids, and related compounds (e.g. terpenoids), and drugs directly affecting function and pathways of the endocannabinoid system as potential test agents.
Applications will be submitted via proposalCENTRAL (https://proposalcentral.com/
). Search “CMCR Grants Program” to locate the application. Please review the attached RFA for instructions. Instructions and document templates can also be found on proposalCENTRAL.
Please see the attached announcement for more details. If you have any questions, or need assistance with your proposal, please contact CMCRgrants@ucsd.edu
PHS 2021-2022 Omnibus Solicitation of the NIH
The 2021-2022 Omnibus Solicitation is open to small business researchers and entrepreneurs working on innovative technologies in translational sciences. Standard deadlines apply. The next due date is April 5, 2022, at 5:00 pm ET.
NCATS is particularly interested in applications that address research areas relevant to any stage of translation, from target validation through pre-clinical and clinical evaluation, to intervention implementation and dissemination, including:
Please note: NCATS will not accept SBIR/STTR applications that include clinical trials under the current Omnibus Solicitation
The National Center for Advancing Translational Science (NCATS) is participating in the NIH Applicant Assistance Program (AAP), a free, 10-week program that helps small businesses apply for Phase I SBIR or STTR funding. AAP provides participants with a dedicated coach with expertise in preparing NIH small business grants and services such as application needs assessment, mentoring, application preparation support, and application review. The program supports the preparation of SBIR or STTR Phase I grants only.
The NIH will begin accepting applications for the April 5, 2022 SBIR/STTR application cycle on Monday November 15, 2021, when the AAP Application Portal opens. The deadline for applications is Friday, December 10, 2021, at 5:00 p.m. ET. Selected participants will be notified in January.
Who Is Eligible?
New applicants, who have not previously applied to the SBIR/STTR program, and do not have an application in review now are eligible to participate in the AAP. Applicants from underrepresented small businesses, especially minority- and women-owned companies, are strongly encouraged to apply.